CYP cynata therapeutics limited

If mesenchymal stem cells don't implant but do cause a change...

  1. 2,282 Posts.
    lightbulb Created with Sketch. 1205
    If mesenchymal stem cells don't implant but do cause a change (like a reset of immune system) then it is quite likely that a single treatment of mscs plus standard of care would show a bigger difference than standard of care and nothing. Why should two treatments versus one treatment of the active (or hoped to be active agent) be a better test than the active agent alone (plus standard of care) versus null?

    It shouldn't - but its easier to sell a trial with that design probably and in patients in countries now demand to be given something - they don't want to take a chance on getting the raw end of the trial lottery and getting treatment or control alone.

    To recruit you need to offer a little something to everyone. Or your GvHD trial may recruit slow or your lung immunity trial might recruit slow - so offer a less effective trial but with a better chance of recruiting - is that really the thinking and to hang with the science of actually showing that there is a real cause behind a real change by doing a real test that is not confounded?
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
16.5¢
Change
0.000(0.00%)
Mkt cap ! $37.28M
Open High Low Value Volume
16.0¢ 16.5¢ 16.0¢ $10.82K 65.84K

Buyers (Bids)

No. Vol. Price($)
2 4450 16.5¢
 

Sellers (Offers)

Price($) Vol. No.
17.0¢ 88474 2
View Market Depth
Last trade - 15.32pm 20/06/2025 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.